Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial

American Journal of Psychiatry

Volumn 165, Issue 10, 2008, Pages 1281-1288

  Bissada, Hany ^a   Tasca, Giorgio A ^a   Barber, Ann Marie ^a   Bradwejn, Jacques ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ANOREXIA NERVOSA; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAY HOSPITAL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; HUMAN; IMPAIRED GLUCOSE TOLERANCE; OBSESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; BODY WEIGHT; COMBINED MODALITY THERAPY; COMPULSIVE BEHAVIOR; DAY CARE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LENGTH OF STAY; OBSESSIVE BEHAVIOR; THINKING; THINNESS;

EID: 52249097471     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.07121900     Document Type: Article

References (40)

1. Hsu LK: Epidemiology of the eating disorders. Psychiatr Clin North Am 1996; 19:681-700
2. Sullivan PF: Mortality in anorexia nervosa. Am J Psychiatry 1995; 152:1073-1074
3. Treat TA, Gaskill JA, McCabe EB, Ghinassi FA, Luczak AD, Marcus MD: Short-term outcome of psychiatric inpatients in the current care environment. Int J Eat Disord 2005; 38:123-133
4. Andersen AE: Treatment of eating disorders in the context of managed health care in the United States: a clinician's perspective, in Treating Eating Disorders: Ethical, Legal, and Personal Issues. Edited by Vandereycken W, Beumont PJ. New York, New York University Press, 1998, pp 261-282
5. Howard WT, Evans KK, Quintero-Howard CV, Bowers WA, Andersen AE: Predictors of success or failure of transition to day hospital treatment for inpatients with anorexia nervosa. Am J Psychiatry 1999; 156:1697-1702
6. Attia E, Haiman C, Walsh BT, Flater SR: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998; 155:548-551
7. Ferguson CP, La Via MC, Crossan PJ, Kaye WH: Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord 1999; 25:11-17
8. Peterson CB, Mitchell JE: Psychosocial and pharmacological treatment of eating disorders: a review of research findings. J Clin Psychol 1999; 55:685-697
9. Strober M, Pataki C, Freeman R, DeAntonio M: No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: an historical case-control study. J Child Adolesc Psychopharmacol 1999; 9:195-201
10. Dally PJ, Sargant W: A new treatment of anorexia nervosa. Br Med J 1960; 1:1770-1773
11. Dally P, Sargant W: Treatment and outcome of anorexia nervosa. Br Med J 1966; 2:793-795
12. Vandereycken W, Pierloot R: Pimozide combined with behaviour therapy in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 1982; 66:445-450
13. Vandereycken W: Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride. Br J Psychiatry 1984; 144:288-292
14. Wilson GT, Grilo CM, Vitousek KM: Psychological treatment of eating disorders. Am Psychol 2007; 62:199-216
15. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
16. Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250-258
17. Garner DM, Garfinkel PE: Handbook of Treatment for Eating Disorders, 2nd ed. New York, Guilford, 1997
18. Dunican KC, DelDotto D: The role of olanzapine in the treatment of anorexia nervosa. Ann Pharmacother 2007; 41:111-115
19. Powers PS, Santana CA, Bannon YS: Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 2002; 32:146-154
20. Barbarich NC, McConaha CW, Gaskill J, La Via M, Frank GK, Achenbach S, Plotnicov KH, Kaye WH: An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 2004; 65:1480-1482
21. La Via MC, Gray N, Kaye WH: Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord 2000; 27:363-366
22. Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont P: Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry 2005; 13:72-75
23. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, Ramaciotti C, Bondi E, Mellado C, Borriello R, Monteleone P: Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol 2007; 22:197-204
24. Gueorguieva R, Krystal JH: Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004; 61:310-317
25. Olmsted MP, McFarlane T, Molleken L, Kaplan AS: Day hospital treatment for eating disorders, in Gabbard's Treatments of Psychiatric Disorders, 3rd ed. Edited by Gabbard GO. Washington, DC, American Psychiatric Press, 2001
26. Zipfel S, Reas DL, Thornton C, Olmsted MP, Williamson DA, Gerlinghoff M, Herzog W, Beumont PJ: Day hospitalization programs for eating disorders: a systematic review of the literature. Int J Eat Disord 2002; 31:105-117
27. Tasca GA, Taylor D, Bissada H, Ritchie K, Balfour L: Attachment predicts treatment completion in an eating disorders partial hospital program among women with anorexia nervosa. J Pers Assess 2004; 83:201-212
28. Morey LC: Personality Assessment Inventory (PAI): Professional Manual. Odessa, Fla, Psychological Assessment Resources, 1991
29. Tasca GA, Wood J, Demidenko N, Bissada H: Using the PAI with an eating disordered population: scale characteristics, factor structure, and differences among diagnostic groups. J Pers Assess 2002; 79:337-356
30. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1011
31. Speranza M, Corcos M, Godart N, Loas G, Guilbaud O, Jeammet P, Flament M: Obsessive compulsive disorders in eating disorders. Eat Behav 2001; 2:193-207
32. Raudenbush SW, Bryk AS: Hierarchical Linear Models: Applications and Data Analysis Methods, 2nd ed. Thousand Oaks, Calif, Sage Publications, 2002
33. Singer JD, Willet JB: Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York, Oxford University Press, 2003
34. Hox J: Multilevel Analysis: Techniques and Applications. Mahwah, NJ, Lawrence Erlbaum Associates, 2002
35. Simpson HB, Petkova E, Cheng J, Huppert J, Foa E, Liebowitz MR: Statistical choices can affect inferences about treatment efficacy: a case study from obsessive-compulsive disorder research. J Psychiatr Res 2007 (Epub ahead of print)
36. Fairburn CG, Agras WS, Walsh BT, Wilson GT, Stice E: Prediction of outcome in bulimia nervosa by early change in treatment. Am J Psychiatry 2004; 161:2322-2324
37. Zoler ML: Antipsychotics linked to weight gain, diabetes. Clin Psychiatry News 1999; 27:20
38. McIntyre RS, McCann SM, Kennedy SH: Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46:273-281
39. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF: Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007; 61:1356-1370
40. Canadian Diabetes Association: 2003 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27(suppl 2):S1-S140